Positive meeting with Medical Products Agency prior to clinical Phase II trial
Redwood Pharma has met with the Swedish Medical Products Agency in an advisory discussion. The meeting gave the company the opportunity to present its development and clinical plans for RP101, which will be tested in a clinical Phase II study in women suffering from chronic dry eye disease.About RP101 RP101 is the company’s lead program for the development of a novel treatment of chronic dry eye disease in postmenopausal women. The active substance is an endogenous small molecule already proven safe and effective and has been formulated in IntelliGel to control its release, reduce dosing